Continuing Application. In the event of a Transfer by a Stockholder of less than all of the Shares pursuant to Article II, the provisions of Section 4.01 shall continue to apply during the term of this Agreement to all Shares Beneficially Owned by the Stockholder.
Continuing Application. The provisions of this Clause Thirty-One shall remain in full force and effect and shall survive the termination or rescission of this Agreement, for any reason whatsoever.
Continuing Application. The provisions of this contract shall remain in full force and effect in so far as they remain to be performed and observed after completion of the sale and purchase of the Property.
Continuing Application. If the Consideration Shares subject to an Offer not accepted by the Purchaser or any assignee are not sold to a Third Party under section 2.8(c)(i) within the period of ninety (90) days referred to therein or sold in the open market under section 2.8(c)(ii) within the period of one (1) year from the date of the Offer, the provisions of this section 2.8 shall again apply.
Continuing Application. The provisions of this Clause Twenty-Nine will remain effective and must survive the termination of this Contract.
Continuing Application. No later than thirty (30) days following the EFFECTIVE DATE, ENTREMED shall file, in the United States and any other country or region possible, a continuing patent application claiming priority to the United States Patent Application 08/102,767 (filed August 6, 1993) claiming the use of derivatives of 2-methoxyestradiol as anti-angiogenesis agents for conditions including ocular neovascularization, wherein the molecule is substituted at the 2 position of the estradiol ring with a) alkoxy groups and b) alkyl esters. ENTREMED shall file a petition to make special pursuant to 37 CFR 1.102 (d) with the United States Patent and Trademark Office in reference to such continuing application, and shall take all reasonable action to accelerate the prosecution of such application(s). ENTREMED shall also submit an Information Disclosure Statement at the time of United States filing of such continuing application which shall inform the Patent Examiner of the existence of U.S. Patent No 6,011,023 (Xxxxx et al.) and U.S. Patent No. 5,643,900 (Fotsis et al.) and all other references which are required to be disclosed pursuant to 37 CFR Section 1.56. ALLERGAN shall pay ENTREMED * Dollars ($*) upon issue of a U.S. patent containing claims substantially as described in this Section 8.2.
Continuing Application. The terms of this Agreement will continue to apply throughout the Executive’s employment, regardless of:
a) the Executive’s length of service; or
b) any changes that may occur to the Executive’s position, duties and responsibilities, compensation or benefits, or other terms of employment; or
c) any changes to the Company as a result of a reorganization, plan of arrangement, reverse take-over, merger or acquisition.
Continuing Application. The Warrantholders Agreement is hereby amended by deleting the second parenthetical clause of the second recital thereof in its entirety and replacing it with the following:
Continuing Application. 12 11.4 Acknowledgment...........................................13
Continuing Application. The terms of this Agreement will continue to apply throughout the Executive’s employment, regardless of:
a) the Executive’s length of service; or
b) any changes that may occur to the Executive’s position, duties and responsibilities, compensation or benefits, or other terms of employment; or
c) any changes to the Company as a result of a reorganization, plan of arrangement, reverse take-over, merger or acquisition; unless the Executive and KMSC agree otherwise in writing. Without limiting the generality of the foregoing, Subsection 4.2(Termination by the KMSC Without Just Cause) and Subsection 7.2(Non-Solicitation) will continue to apply throughout the Executive’s employment (and for the period after termination as stated in Subsection 7.2), regardless of his length of service or any changes that may occur to his position, duties and responsibilities, compensation or benefits, or other terms of employment, unless the Executive and KMSC agree otherwise in writing.
